Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; a national prospective cohort study in Norway from 2015 to 2017

Table 2 The proportion of patients on OAT were dispensed ADHD medication categorized on medical diagnoses and types of CAS

a)
Year	2015		2016		2017
Year	All indications
Number of patients	274		312		349
ADHD medication	No.	%^a	No.	%^a	No.	%^a
Methylphenidate	194	71	217	70	207	59
- short- and intermediate-acting^b	182	66	206	66	193	55
- long-acting^c	38	14	30	10	33	9
Dexamphetamine	63	23	64	21	60	17
Atomoxetine	23	8	26	8	21	6
Lisdexamphetamine	14	5	47	15	84	24
Racemic amphetamine	< 5	0	< 5	1	8	2
b)
Year	2015		2016		2017
Year	ADHD
Number of patients	223		270		312
ADHD medication	No.	%^a	No.	%^a	No.	%^a
Methylphenidate	171	76	198	72	194	62
- short- and intermediate-acting^b	163	73	190	70	182	58
- long-acting^c	32	14	26	10	29	9
Dexamphetamine	45	20	55	20	53	17
Atomoxetine	12	5	19	7	16	5
Lisdexamphetamine	12	5	39	14	72	23
Racemic amphetamine	< 5	< 5	< 5	< 5	7	2

ADHD Attention deficit hyperactivity disorder, ADHD medication = atomoxetine, racemic amphetamine, dexamphetamine, lisdexamphetamine, and methylphenidate, ICD-10 10th Revision of International Classification of Diseases, ICPC2 International Classification of Primary Care 2, and OAT opioid agonist therapy
^a Per cent of patients who received OAT and CAS, ^b Include all tablets and capsules with short- and intermediate-acting methylphenidate, ^c Include depot formulations of methylphenidate (Concerta®, Delmosart®, Equasym Depot®, or Methylphenidate Sandoz®)
The tables display patients on OAT who were dispensed an ADHD medication in the period 2015 to 2017 categorized on a) all medical indications, and b) ADHD (ICD-10 code: F90 or ICPC2 code: P81)

ISSN: 1471-244X